HAMBURG, GERMANY / ACCESSWIRE / April 24, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today reported financial results and corporate updates for the fiscal year ended 31 December 2023 and announced a priority reset to optimise its business to meet evolving market demand and focus on profitable growth in 2024 and beyond.
HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc. today announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis.
Evotec and Variant Bio Partner to Discover & Develop Treatments for Fibrosis
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024.
Evotec says it promptly reported share trades withheld by former CEO
? Werner Lanthaler announced his resignation as CEO of serial Big Pharma partner Evotec on Wednesday, and his former COO Mario Polywka will fill in as interim chief until a permanent successor is named. Under Lanthaler’s leadership, Evotec has formed alliances with Takeda (RNA), Bristol Myers Squibb (neuro diseases), Eli Lilly (metabolic diseases) and Novo Nordisk (kidney diseases), among many others.
PARTNERSHIP TO ACCELERATE DEWPOINT™S LEADING ONCOLOGY PIPELINE PROGRAMS TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC™S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY...